ExeVir’s unique platform uses heavy chain-only (VHH) antibody fragments derived from camelid single-domain antibodies. The small size and flexibility of the VHH antibody fragments means they can be used like building blocks – linked together into a single drug molecule capable of addressing multiple targets on a bacterial cell or viral particle. These multi-specific antibodies are particularly helpful in tackling fast-moving mutations, giving ExeVir therapies an advantage against disease variants and subtypes.
Thanks to the short throughput time needed to generate new drug candidates, ExeVir’s modular platform can be used to respond rapidly to existing and future threats to public health. The resulting therapeutics are stable, cost-effective, and easy to produce, facilitating global access to protection and treatment.
ExeVir collaborates closely Belgium’s leading life sciences research institute VIB, developing new VHH antibodies together with the laboratories of Prof. Xavier Saelens and Prof. Nico Callewaert (VIB – Ghent University).
In a world where proximity, travel, and climate change give rise to increasing incidences and rapidly spreading of infectious diseases, the COVID-19 pandemic reminded us how important it is to tackle infectious diseases through both prevention and treatment. To stay ahead of this evolutionary arms race, we need to invest preemptively in innovative platforms that can provide solutions to current infectious diseases and respond to outbreaks with speed and agility.
ExeVir is doing its part to tackle the growing impact of infectious diseases by building a progressive pipeline of therapies, with an initial focus on COVID-19 protection for the immunocompromised populations. ExeVir’s pipeline includes:
Diseases like COVID-19 disproportionately impact and threaten immunocompromised populations. There are many reasons people may fall into this category, including cancer treatments, organ transplants, immunosuppressive therapies, and immunodeficiencies. These people remain vulnerable despite vaccinations – they need better protection both now and in the future.
Fortunately, the modular nature of ExeVir’s VHH platform enables rapid development of effective therapeutics to protect those among us at highest risk. ExeVir aims to develop antibody treatments against diseases like COVID-19 to help protect and treat the most vulnerable patients in our societies.
ExeVir is backed by a strong international investor syndicate: the company’s €42 million Series A was led by Fund+ and backed by UCB Ventures, FPIM, V-Bio Ventures, VIB, SRIW, Noshaq, Vives IUF and SambrInvest. ExeVir has also raised €16.5 million in non-dilutive funding from Horizon Europe, VLAIO, and the DG06.
Do you have any questions about ExeVir’s technology, send us a message!